CAS: 16114-47-9; 3,5-Dimethylisoxazole-4-Boronic Acid

相似化合物

832114-00-8 1008139-25-0 1111732-84-3

上下游产品

CAS号10558-25-5 4-溴-3,5-二甲基异噁唑 | CAS号5419-55-6 硼酸三异丙酯 | CAS号300-87-8 3,5-二甲基异唑 | CAS号10557-85-4 4-碘-3,5-二甲基异恶唑 | CAS号10557-85-4 4-碘-3,5-二甲基异恶唑 | CAS号1300031-49-5 7-(3,5-二甲基异噁唑-4... | CAS号1138472-98-6 4-(5-(3,5-二甲基异噁...

3,5-二甲基异唑置于n-溴代丁二酰亚胺(Nbs),正丁基锂体系中,用 四氢呋喃,N,N-二甲基甲酰胺 用作溶剂,化学反应 19.5H,反应生成3,5-二甲基异恶唑-4-硼酸
参考文献: Agonists Of Gpr40[fr] Agonistes De Gpr40
标题: Agonists Of Gpr40[fr] Agonistes De Gpr40
摘要:本发明涉及具有调节gpr40活性能力的化合物,因此在治疗与gpr40相关的疾病方面具有用处.此外,该发明涉及这些化合物,其制备方法,含有这些化合物的药物组合物以及在治疗与gpr40活性相关的某些疾病方面使用这些化合物的用途.

专利信息

专利号:US-12150934-B2
优先权日:2016-11-30
标 题 :Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
发明人：SIDDIQUI ARSHAD M; CIBLAT STEPHANE; CONSTANTINEAU-FORGET LEA; GRAND-MAITRE CHANTAL; GUO XIANGYU; SRIVASTAVA SANJAY; SHIPPS GERALD W; COOPER ALAN B; OZA VIBHA; KOSTURA MATTHEW W; LUTHER MICHAEL; LEVINE JEDD
权利人:BANTAM PHARMACEUTICAL LLC
摘要:Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “aâ€?, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

专利号:US-9938258-B2
优先权日:2012-11-29
标 题:Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
发明人：BALOGLU ERKAN; SHECHTER SHARON; SHACHAM SHARON; MCCAULEY DILARA; SENAPEDIS WILLIAM; GOLAN GALI; KALID ORI
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: n nor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

专利号:WO-2010065383-A1
优先权日:2008-11-25
标 题 :Calcilytic compounds
发明人：CASILLAS LINDA N; CHARNLEY ADAM KENNETH; HARRIS PHILIP ANTHONY; JEONG JAE U; MARQUIS ROBERT W; RAMANJULU JOSHI M; TROUT ROBERT
权利人:GLAXOSMITHKLINE LLC; CASILLAS LINDA N; CHARNLEY ADAM KENNETH; HARRIS PHILIP ANTHONY; JEONG JAE U; MARQUIS ROBERT W; RAMANJULU JOSHI M; TROUT ROBERT
摘要:Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.

专利号:US-11794180-B2
优先权日:2015-10-29
标 题 :Tri-(adamantyl)phosphines and applications thereof
发明人：CARROW BRAD P; CHEN LIYE
权利人:UNIV PRINCETON
摘要:In one aspect, phosphine compounds comprising three adamantyl moieties (PAd3) and associated synthetic routes are described herein. Each adamantyl moiety may be the same or different. For example, each adamantyl moiety (Ad) attached to the phosphorus atom can be independently selected from the group consisting of adamantane, diamantane, triamantane and derivatives thereof. Transition metal complexes comprising PAd3 ligands are also provided for catalytic synthesis including catalytic cross-coupling reactions.